AKT1 and cancer: Available strategies for targeting Nrf2 include direct Nrf2 inhibitors (inhibition of protein synthesis, inhibition of Nrf2 transcriptional activity, inhibition of Nrf2 accumulation in the nucleus by Trigonelline, inhibition of P62-Keap1 association, inhibition of PI3K/AKT, inhibition of FN3K, and activation of the Brain-Specific Kinase 2), and alternative ways to target Nrf2/Keap1 mutant cancers (direct inhibition of the cystine/glutamate antiporter system, inhibition of the Pentose phosphate pathway, NQO1 bioactivatable drugs, and Aldo–Keto Reductases) [69].